TCR2 Therapeutics (TCRR) Receives a Hold From Mizuho Securities
TipRanksMay 11, 2023 20:45
TCR2 Therapeutics (TCRR) Was Downgraded to a Hold Rating at Mizuho Securities
TipRanksMar 24, 2023 05:46
Analysts Offer Insights on Healthcare Companies: TCR2 Therapeutics (TCRR) and Inozyme Pharma (INZY)
TipRanksMar 24, 2023 00:36
Wedbush Adjusts TCR2 Therapeutics Price Target to $1.68 From $2.18, Maintains Neutral Rating
MT NewswiresMar 24, 2023 00:36
Analysts Offer Insights on Healthcare Companies: TCR2 Therapeutics (TCRR) and Nurix Therapeutics (NRIX)
TipRanksMar 9, 2023 16:46
Truist Securities Downgrades TCR2 Therapeutics to Hold, Lowers Price Target to $3
BenzingaMar 8, 2023 22:46
Truist Securities Downgrades TCR2 Therapeutics to Hold From Buy, Cuts Price Target to $3 From $8
MT NewswiresMar 8, 2023 03:34
Wedbush Lowers TCR2 Therapeutics' Price Target to $2.18 From $4 on Heels of Adaptimmune Merger Announcement, Keeps Neutral Rating
MT NewswiresMar 7, 2023 20:34
TCR2 Therapeutics (TCRR) Was Downgraded to a Hold Rating at H.C. Wainwright
TipRanksMar 7, 2023 19:21
SVB Securities Keeps Their Hold Rating on TCR2 Therapeutics (TCRR)
TipRanksJan 9, 2023 12:20
Piper Sandler Adjusts Price Target on TCR2 Therapeutics to $10 From $8, Maintains Overweight Rating
MT NewswiresJan 6, 2023 22:45
TCR2 Therapeutics Analyst Ratings
Benzinga Analyst RatingsJan 6, 2023 19:42
Mizuho Securities Remains a Buy on TCR2 Therapeutics (TCRR)
TipRanksJan 6, 2023 05:50
TCR2 Therapeutics Analyst Ratings
Benzinga Analyst RatingsJan 5, 2023 17:37
HC Wainwright Trims Price Target on TCR2 Therapeutics to $13 From $14, Maintains Buy Rating
MT NewswiresNov 21, 2022 20:50
TCR2 Therapeutics Analyst Ratings
Benzinga Analyst RatingsNov 21, 2022 19:56
HC Wainwright & Co. Maintains Buy on TCR2 Therapeutics, Lowers Price Target to $13
Benzinga Real-time NewsNov 21, 2022 19:56
Mizuho Securities Sticks to Their Buy Rating for TCR2 Therapeutics (TCRR)
TipRanksNov 9, 2022 16:35
SVB Leerink Adjusts Price Target on TCR2 Therapeutics to $2 From $3, Maintains Market Perform Rating
MT NewswiresNov 9, 2022 00:55
SVB Securities Keeps Their Hold Rating on TCR2 Therapeutics (TCRR)
TipRanksNov 9, 2022 00:40
No Data
No Data